Neurogastrx, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.neurogastrx.com
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a GLP-1 Agonist
Phase 2
Active, not recruiting
- Conditions
- Overweight and ObesityHealthy
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Neurogastrx, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06500429
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis
Phase 2
Completed
- Conditions
- Diabetic GastroparesisIdiopathic Gastroparesis
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Neurogastrx, Inc.
- Target Recruit Count
- 162
- Registration Number
- NCT04303195
- Locations
- 🇺🇸
Biopharma Informatic, LLC, Houston, Texas, United States
🇺🇸International Research Associates LLC, Miami, Florida, United States
🇺🇸Panax Clinical Research, Miami, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath